CCR8 and neoplasm: Experiments with a surrogate mAb specific for murine CCR8 showed good activity as a single agent or in combination with PD-1 inhibitors in anti-PD-1-resistant murine tumor models [333], suggesting that JTX-1811 would be efficient to deplete CCR8+ Tregs in human solid tumors in favor of the antitumor immune response.